Literature DB >> 7012166

Separate O-grouping schemes for serotyping clinical isolates of Proteus vulgaris and Proteus mirabilis.

J L Penner, J N Hennessy.   

Abstract

Antisera were prepared against type strains of the original scheme of B. Perch (Acta Pathol. Microbiol. Scand. 25:703-714, 1948) and against newly defined types to produce separate schemes for O-grouping Proteus vulgaris and Proteus mirabilis. In assessing the schemes for their effectiveness it was found that 82% of 208 P. vulgaris isolates and 88% of 194 P. mirabilis isolates from two hospitals were typable. Only 3.4% of the P. vulgaris isolates agglutinated in P. mirabilis antisera, and 1.5% of the P. mirabilis agglutinated in P. vulgaris antisera, indicating that separation of the schemes would be more advantageous in routine typing. P. mirabilis of groups O3, O6, O10, O29, and O30 were most frequently isolated. Of the P. vulgaris isolates, 25% belonged to newly defined O-groups, and one of these was the largest with 14% of all isolates of this species. The application of serotyping using separate schemes for each species was advocated in epidemiological studies.

Entities:  

Mesh:

Year:  1980        PMID: 7012166      PMCID: PMC273580          DOI: 10.1128/jcm.12.3.304-309.1980

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Infection due to Proteus mirabilis in newborn nursery.

Authors:  A H BECKER
Journal:  Am J Dis Child       Date:  1962-10

2.  A study of Proteus infections in a male urological ward.

Authors:  P W KIPPAZ
Journal:  J Clin Pathol       Date:  1957-08       Impact factor: 3.411

3.  0 antigen distribution and sensitivity to the bactericidal effect of normal human serum of Proteus strains from clinical specimens.

Authors:  P Larsson; S Olling
Journal:  Med Microbiol Immunol       Date:  1977-07-18       Impact factor: 3.402

4.  Proteus infections in a general hospital. II. Some clinical and epidemiological characteristis. With an analysis of 71 cases of proteus bacteremia.

Authors:  J L Adler; J P Burke; D F Martin; M Finland
Journal:  Ann Intern Med       Date:  1971-10       Impact factor: 25.391

5.  Proteus mirabilis infections in a hospital nursery traced to a human carrier.

Authors:  J P Burke; D Ingall; J O Klein; H M Gezon; M Finland
Journal:  N Engl J Med       Date:  1971-01-21       Impact factor: 91.245

6.  Differentiation of Proteus mirabilis by bacteriophage typing and the Dienes reaction.

Authors:  F W Hickman; J J Farmer
Journal:  J Clin Microbiol       Date:  1976-03       Impact factor: 5.948

7.  Serotyping in epidemiological tracing of nosocomially acquired Proteus mirabilis in a geriatric ward.

Authors:  P Larsson; H E Andersson; B Norlén
Journal:  Infection       Date:  1978       Impact factor: 3.553

8.  Serotyping and the Dienes reaction on Proteus mirabilis from hospital infections.

Authors:  J De Louvois
Journal:  J Clin Pathol       Date:  1969-05       Impact factor: 3.411

9.  [Studies of the typing of Salmonella R forms. I. Microbiological and serological studies of Salmonella minnesota mutants].

Authors:  G Schmidt; S Schlecht; O Lüderitz; O Westphal
Journal:  Zentralbl Bakteriol Orig       Date:  1969

10.  Observations on indol-positive Proteus.

Authors:  A Von Graevenitz; H Spector
Journal:  Yale J Biol Med       Date:  1969-06
View more
  12 in total

1.  Molecular and genetic analyses of the putative Proteus O antigen gene locus.

Authors:  Quan Wang; Agnieszka Torzewska; Xiaojuan Ruan; Xiaoting Wang; Antoni Rozalski; Zhujun Shao; Xi Guo; Haijian Zhou; Lu Feng; Lei Wang
Journal:  Appl Environ Microbiol       Date:  2010-06-25       Impact factor: 4.792

2.  Functional identification of the Proteus mirabilis core lipopolysaccharide biosynthesis genes.

Authors:  Eleonora Aquilini; Joana Azevedo; Natalia Jimenez; Lamiaa Bouamama; Juan M Tomás; Miguel Regué
Journal:  J Bacteriol       Date:  2010-07-09       Impact factor: 3.490

3.  Capsule structure of Proteus mirabilis (ATCC 49565).

Authors:  L M Beynon; A J Dumanski; R J McLean; L L MacLean; J C Richards; M B Perry
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

4.  Three enzymatic steps required for the galactosamine incorporation into core lipopolysaccharide.

Authors:  Eleonora Aquilini; Joana Azevedo; Susana Merino; Natalia Jimenez; Juan M Tomás; Miguel Regué
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

Review 5.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

6.  Speciation, serotyping, antimicrobial sensitivity and plasmid content of Proteeae from the environment of calf-rearing units in South West England.

Authors:  P M Hawkey; J L Penner; A H Linton; C A Hawkey; L J Crisp; M Hinton
Journal:  J Hyg (Lond)       Date:  1986-12

7.  Outer membrane protein profiles and multilocus enzyme electrophoresis analysis for differentiation of clinical isolates of Proteus mirabilis and Proteus vulgaris.

Authors:  T Kappos; M A John; Z Hussain; M A Valvano
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

8.  Serious nosocomial infection caused by Morganella morganii and Proteus mirabilis in a cardiac surgery unit.

Authors:  E W Williams; P M Hawkey; J L Penner; B W Senior; L J Barton
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

9.  Serological and structural characterization of the O-antigens of the unclassified Proteus mirabilis strains TG 83, TG 319, and CCUG 10700 (OA).

Authors:  Agnieszka Zabłotni; Krystyna Zych; Anna N Kondakova; Małgorzata Siwińska; Yuriy A Knirel; Zygmunt Sidorczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Sep-Oct       Impact factor: 4.291

10.  Serological classification and epitope specificity of Proteus vulgaris TG 251 from Proteus serogroup O65.

Authors:  Krystyna Zych; Katarzyna Kołodziejska; Dominika Drzewiecka; Andrey V Perepelov; Yuriy A Knirel; Zygmunt Sidorczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-06-08       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.